Specific mutations in some tumor suppressor genes such as p53 can act in a dominant fashion. We tested whether this mechanism may also apply for the neurofibromatosis type-2 gene (NF2) which, when mutated, leads to schwannoma development. Transgenic mice were generated that express, in Schwann cells, mutant NF2 proteins prototypic of natural mutants observed in humans. Mice expressing a NF2 protein with an interstitial deletion in the amino-terminal domain showed high prevalence of Schwann cell-derived tumors and Schwann cell hyperplasia, whereas those expressing a carboxy-terminally truncated protein were normal. Our results indicate that a subset of mutant NF2 alleles observed in patients may encode products with dominant properties when overexpressed in specific cell lineages.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC316642 | PMC |
| http://dx.doi.org/10.1101/gad.13.8.978 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Alternative driver pathways in peripheral nerve sheath tumors - including DICER1 and/or KRAS alterations.
J Pathol
January 2025
Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
DICER1-associated sarcoma is an emerging entity, defined by either somatic or germline dicer 1, ribonuclease III (DICER1) mutations and sharing characteristic morphologic features irrespective of the site of origin. In addition to the DICER1 driver mutation, concurrent genomic alterations, including tumor protein 53 (TP53) inactivation and RAS pathway activation, are frequently detected. Tumors that morphologically resemble malignant peripheral nerve sheath tumor (MPNST) have rarely been reported among DICER1 sarcomas and often pose diagnostic challenges.
View Article and Find Full Text PDFRole of Mutation in the Development of Eleven Different Cancers.
Cancers (Basel)
December 2024
Department of Neurosurgery, Baylor College of Medicine, Houston, TX 77030, USA.
: With the rise in prevalence of diagnostic genetic techniques like RNA sequencing and whole exome sequencing (WES), as well as biological treatment regiments for cancer therapy, several genes have been implicated in carcinogenesis. This review aims to update our understanding of the Neurofibromatosis 2 (NF2) gene and its role in the pathogenesis of various cancers. : A comprehensive search of five online databases yielded 43 studies that highlighted the effect of sporadic NF2 mutations on several cancers, including sporadic meningioma, ependymoma, schwannoma, mesothelioma, breast cancer, hepatocellular carcinoma, prostate cancer, glioblastoma, thyroid cancer, and melanoma.
View Article and Find Full Text PDFMutant RIT1 cooperates with YAP to drive an EMT-like lung cancer state.
bioRxiv
November 2024
Human Biology Division, Fred Hutchinson Cancer Center, Seattle, WA 98109.
The discovery of oncogene addiction in cancer has led to the development of over a dozen FDA-approved biomarker-driven therapies in lung adenocarcinoma. Somatic mutations of the "Ras-like in all tissues" (RIT1) gene are non-canonical driver events in lung cancer, occurring in ~2% of lung adenocarcinomas in a mutually exclusive fashion with and mutations. Patients with -mutant lung cancer lack targeted therapy treatment options, and a lack of pre-clinical models has hindered the development of therapeutic strategies for -mutant lung cancer.
View Article and Find Full Text PDFInteractions among Merlin, Arkadia, and SKOR2 mediate NF2-associated Schwann cell proliferation in human.
bioRxiv
September 2024
Department of Otolaryngology, University of Miami Miller School of Medicine, Miami, FL, 33136, United States.
Article Synopsis
- - NF2-Related Schwannomatosis is a genetic disease linked to mutations in the merlin gene, which is crucial for preventing tumors, particularly bilateral vestibular schwannomas.
- - Researchers used human induced pluripotent stem cells (hiPSCs) to study how these NF2 mutations affect Schwann cells, revealing that NF2 mutant Schwann cells display abnormal shapes and increased growth.
- - The study identified new interaction partners for the merlin protein, specifically Arkadia and SKOR2, and found that their interaction is essential for properly activating a specific pathway involved in cell signaling.
Aggressive high-grade NF2 mutant meningiomas downregulate oncogenic YAP signaling via the upregulation of VGLL4 and FAT3/4.
Neurooncol Adv
August 2024
Department of Neurosurgery, Clinical Neurosciences Center, University of Utah, Salt Lake City, Utah, USA.
Article Synopsis
- Meningiomas are the most common primary brain tumors in adults, with some being benign and others high-grade and fatal; about 50% have mutations in the NF2 gene which affect YAP1 activity.
- The study analyzed RNA-Seq data and in vitro experiments to compare YAP1 target genes and Hippo effectors in benign versus aggressive NF2 mutant meningiomas.
- Findings revealed that aggressive meningiomas show lower YAP1 target gene expression but higher VGLL4 and FAT3/4 levels, suggesting a link between VGLL4 expression and reduced YAP activity, which may influence treatment strategies targeting YAP1 in these tumors.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!